Related Experiment Video

Updated: Jul 18, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
08:23

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds

Published on: February 16, 2022

Nitric oxide synthase inhibitors in post-myocardial infarction cardiogenic shock--an update

Edo Kaluski1, Alberto Hendler, Alex Blatt

  • 1Department of Cardiology, Assaf Harofeh Medical Center, Zrifin, Israel. ekaluski@gmail.com

Clinical Cardiology
|December 1, 2006
PubMed

Insights

Cardiogenic shock (CS) after heart attack remains deadly, with nitric oxide (NO) overproduction worsening outcomes. This review examines NO

Area of Science:

  • Cardiovascular Medicine
  • Critical Care Medicine
  • Pharmacology

Background:

  • Cardiogenic shock (CS) following acute myocardial infarction (AMI) has a high mortality rate (50%) despite interventions like coronary angioplasty.
  • Patients experience a systemic metabolic crisis due to extensive myocardial damage and stunning.
  • Overproduction of nitric oxide (NO) plays a significant role in the pathophysiology of CS.

Purpose of the Study:

  • To review the physiological effects of nitric oxide (NO) and nitric oxide synthase (NOS) inhibitors on the cardiovascular system in the context of CS.
  • To summarize existing clinical trial data on the safety and efficacy of NOS inhibitors for treating CS.

Main Methods:

  • Literature review of current data on NO and NOS inhibitors' cardiovascular effects.
  • Summary of clinical trials investigating NOS inhibitors in CS patients.

Main Results:

  • Nitric oxide (NO) overproduction is implicated in the severe metabolic disturbances seen in CS.
  • Data on the cardiovascular effects of NO and NOS inhibitors are presented.
  • Clinical trial evidence regarding the safety and efficacy of NOS inhibitors in CS is summarized.

Conclusions:

  • Nitric oxide (NO) and its related enzymes are critical targets for understanding and potentially treating cardiogenic shock.
  • Further research and clinical trials are needed to establish the role of nitric oxide synthase (NOS) inhibitors in managing CS.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...